JP5814488B2 - ジヒドロピリダジン−３，５−ジオン誘導体 - Google Patents
ジヒドロピリダジン−３，５−ジオン誘導体 Download PDFInfo
- Publication number
- JP5814488B2 JP5814488B2 JP2015505576A JP2015505576A JP5814488B2 JP 5814488 B2 JP5814488 B2 JP 5814488B2 JP 2015505576 A JP2015505576 A JP 2015505576A JP 2015505576 A JP2015505576 A JP 2015505576A JP 5814488 B2 JP5814488 B2 JP 5814488B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- trifluoromethyl
- phenyl
- hydroxy
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCCC(CCCC#N)(C(CC)C(C)C(C)CC1)C(C)=C(C(C2C(CCCCN)**2)=C)C1=C Chemical compound CCCC(CCCC#N)(C(CC)C(C)C(C)CC1)C(C)=C(C(C2C(CCCCN)**2)=C)C1=C 0.000 description 10
- VBRYHICLOXVNPA-UHFFFAOYSA-N CC(C)(C)OC(CCOCCOCCOCCO[O](c1ccc(C)cc1)([O-])=O)=O Chemical compound CC(C)(C)OC(CCOCCOCCOCCO[O](c1ccc(C)cc1)([O-])=O)=O VBRYHICLOXVNPA-UHFFFAOYSA-N 0.000 description 1
- PKCFPJQEQDLKSD-UHFFFAOYSA-N CC(C)(C)OC(CCOCCOCCOc(ccc(CN1N(C)C2(CCCC2)C(O)=C(C(Nc(ccc(C(F)(F)F)c2)c2-c2cc(C(F)(F)F)ncn2)=O)C1=O)c1F)c1F)=O Chemical compound CC(C)(C)OC(CCOCCOCCOc(ccc(CN1N(C)C2(CCCC2)C(O)=C(C(Nc(ccc(C(F)(F)F)c2)c2-c2cc(C(F)(F)F)ncn2)=O)C1=O)c1F)c1F)=O PKCFPJQEQDLKSD-UHFFFAOYSA-N 0.000 description 1
- DZPNUKRUYMUIMD-SNVBAGLBSA-N CC1(C)O[C@H](COCCCCCBr)CO1 Chemical compound CC1(C)O[C@H](COCCCCCBr)CO1 DZPNUKRUYMUIMD-SNVBAGLBSA-N 0.000 description 1
- PRJJXRMUMFKBRM-SECBINFHSA-N CC1(C)O[C@H](COCCC[Br]=C)CO1 Chemical compound CC1(C)O[C@H](COCCC[Br]=C)CO1 PRJJXRMUMFKBRM-SECBINFHSA-N 0.000 description 1
- VBRDIAXHJGPFQK-UHFFFAOYSA-N CCc(c(F)c(CN(C(CC(Nc(ccc(C(F)(F)F)c1)c1-c1ncnc(C(F)(F)F)c1)=O)=O)N(C)C1(CCC1)C(OC)=O)cc1)c1OCCN1CCOCC1 Chemical compound CCc(c(F)c(CN(C(CC(Nc(ccc(C(F)(F)F)c1)c1-c1ncnc(C(F)(F)F)c1)=O)=O)N(C)C1(CCC1)C(OC)=O)cc1)c1OCCN1CCOCC1 VBRDIAXHJGPFQK-UHFFFAOYSA-N 0.000 description 1
- CSIPMPYXUPIYEG-BUVRLJJBSA-N CN(CCOC)CCOc(ccc(/C=N/N(C)C1(CCCC1)C(OC)=O)c1F)c1F Chemical compound CN(CCOC)CCOc(ccc(/C=N/N(C)C1(CCCC1)C(OC)=O)c1F)c1F CSIPMPYXUPIYEG-BUVRLJJBSA-N 0.000 description 1
- CLLBVZMAXCBAFJ-UHFFFAOYSA-N CNC1(CCCC1)C(OC)=O Chemical compound CNC1(CCCC1)C(OC)=O CLLBVZMAXCBAFJ-UHFFFAOYSA-N 0.000 description 1
- XEMMEFHPILYXGE-AREMUKBSSA-N C[C@@](CCC1)(C(O)=C2C(Nc(ccc(C(F)(F)F)c3)c3-c3ncnc(C(F)(F)F)c3)=O)N1N(Cc(cccc1F)c1F)C2=O Chemical compound C[C@@](CCC1)(C(O)=C2C(Nc(ccc(C(F)(F)F)c3)c3-c3ncnc(C(F)(F)F)c3)=O)N1N(Cc(cccc1F)c1F)C2=O XEMMEFHPILYXGE-AREMUKBSSA-N 0.000 description 1
- DVKOGENZDLVFML-UHFFFAOYSA-N F[B](CN1CCOCC1)(F)[FH+] Chemical compound F[B](CN1CCOCC1)(F)[FH+] DVKOGENZDLVFML-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Luminescent Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015505576A JP5814488B2 (ja) | 2013-03-13 | 2014-03-13 | ジヒドロピリダジン−３，５−ジオン誘導体 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013051082 | 2013-03-13 | ||
| JP2013051082 | 2013-03-13 | ||
| JP2013132889 | 2013-06-25 | ||
| JP2013132889 | 2013-06-25 | ||
| JP2015505576A JP5814488B2 (ja) | 2013-03-13 | 2014-03-13 | ジヒドロピリダジン−３，５−ジオン誘導体 |
| PCT/JP2014/056778 WO2014142273A1 (ja) | 2013-03-13 | 2014-03-13 | ジヒドロピリダジン－３，５－ジオン誘導体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015182722A Division JP6420738B2 (ja) | 2013-03-13 | 2015-09-16 | ジヒドロピリダジン−３，５−ジオン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP5814488B2 true JP5814488B2 (ja) | 2015-11-17 |
| JPWO2014142273A1 JPWO2014142273A1 (ja) | 2017-02-16 |
Family
ID=51536921
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015505576A Active JP5814488B2 (ja) | 2013-03-13 | 2014-03-13 | ジヒドロピリダジン−３，５−ジオン誘導体 |
| JP2015182722A Active JP6420738B2 (ja) | 2013-03-13 | 2015-09-16 | ジヒドロピリダジン−３，５−ジオン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015182722A Active JP6420738B2 (ja) | 2013-03-13 | 2015-09-16 | ジヒドロピリダジン−３，５−ジオン誘導体 |
Country Status (29)
| Country | Link |
|---|---|
| EP (2) | EP3757093A1 (enExample) |
| JP (2) | JP5814488B2 (enExample) |
| KR (2) | KR102072268B1 (enExample) |
| CN (1) | CN105073715B (enExample) |
| AU (1) | AU2014230552B2 (enExample) |
| BR (1) | BR112015022092B1 (enExample) |
| CA (1) | CA2901868C (enExample) |
| CL (1) | CL2015002543A1 (enExample) |
| CR (1) | CR20150505A (enExample) |
| DK (1) | DK2975030T3 (enExample) |
| ES (1) | ES2811126T3 (enExample) |
| HR (1) | HRP20201211T1 (enExample) |
| HU (1) | HUE050577T2 (enExample) |
| IL (1) | IL240825B (enExample) |
| LT (1) | LT2975030T (enExample) |
| MX (1) | MX376532B (enExample) |
| MY (1) | MY174269A (enExample) |
| NZ (1) | NZ711182A (enExample) |
| PE (1) | PE20151535A1 (enExample) |
| PH (1) | PH12015501940A1 (enExample) |
| PL (1) | PL2975030T3 (enExample) |
| PT (1) | PT2975030T (enExample) |
| RS (1) | RS60911B1 (enExample) |
| RU (1) | RU2662832C2 (enExample) |
| SG (1) | SG11201507345RA (enExample) |
| SI (1) | SI2975030T1 (enExample) |
| TW (2) | TWI683811B (enExample) |
| UA (1) | UA118755C2 (enExample) |
| WO (1) | WO2014142273A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016040262A (ja) * | 2013-03-13 | 2016-03-24 | 中外製薬株式会社 | ジヒドロピリダジン−３，５−ジオン誘導体 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4374877A3 (en) * | 2014-09-12 | 2024-07-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor and phosphorus adsorbent for use in the prevention, treatment or suppression of chronic kidney disease, arteriosclerosis associated with vascular calcification, or ectopic calcification. |
| WO2018019721A1 (en) | 2016-07-26 | 2018-02-01 | Basf Se | Herbicidal pyridine compounds |
| WO2018019755A1 (en) | 2016-07-26 | 2018-02-01 | Basf Se | Herbicidal pyridine compounds |
| CN110885290A (zh) * | 2019-12-16 | 2020-03-17 | 阿里生物新材料（常州）有限公司 | 一种3-氟-2-甲基-4-三氟甲基苯胺盐酸盐的合成方法 |
| CN115734965B (zh) | 2020-06-26 | 2025-05-02 | 日本农药株式会社 | 芳基四氢哒嗪衍生物或其盐类、和含有该化合物的杀虫剂及其使用方法 |
| WO2022221182A1 (en) * | 2021-04-12 | 2022-10-20 | Jnana Therapeutics Inc. | Small molecule inhibitors of mammalian slc34a1 function |
| WO2022260064A1 (ja) | 2021-06-08 | 2022-12-15 | 中外製薬株式会社 | ジヒドロピリダジン－３，５－ジオン誘導体を含有する製剤 |
| AR126060A1 (es) * | 2021-06-08 | 2023-09-06 | Chugai Pharmaceutical Co Ltd | Método para producir derivado de dihidropiridazin-3,5-diona |
| CA3244263A1 (en) | 2021-12-28 | 2025-06-13 | Nihon Nohyaku Co., Ltd. | ARYL TETRAHYDROPYRIDAZINE DERIVATIVE OR SALT THEREOF, PESTICIDE CONTAINING SAID COMPOUND AND ASSOCIATED METHOD OF USE |
| WO2023219127A1 (ja) | 2022-05-11 | 2023-11-16 | 中外製薬株式会社 | 嚢胞性疾患を治療または予防するための医薬組成物 |
| CN116217862A (zh) * | 2023-03-21 | 2023-06-06 | 中国农业科学院农业环境与可持续发展研究所 | 一种可降解生物膜助剂的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100663147B1 (ko) * | 2002-02-19 | 2007-02-28 | 오노 야꾸힝 고교 가부시키가이샤 | 축합 피리다진 유도체 화합물 및 이를 유효 성분으로서함유하는 약제 |
| CN1662529A (zh) * | 2002-06-19 | 2005-08-31 | 默克专利有限公司 | 作为磷酸二酯酶iv抑制剂的噻唑衍生物 |
| TWI441637B (zh) * | 2005-05-18 | 2014-06-21 | Array Biopharma Inc | Ｍｅｋ雜環抑制劑及其使用方法 |
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| UA97498C2 (ru) * | 2006-11-03 | 2012-02-27 | Басф Се | Способ получения дифторметилпиразолилкарбоксилатов |
| TW201006821A (en) * | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| CN102264740B (zh) * | 2008-08-20 | 2014-10-15 | 菲布罗根有限公司 | 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途 |
| WO2011048611A1 (en) * | 2009-10-07 | 2011-04-28 | Torrent Pharmaceuticals Limited | Novel fused pyridazine derivatives |
| MX2012012421A (es) * | 2010-04-28 | 2012-12-17 | Astellas Pharma Inc | Compuestos tetrahidrobenzotiofena. |
| EP2590965B1 (en) * | 2010-07-07 | 2016-04-20 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| EP2591354B1 (en) | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| PL2772490T3 (pl) | 2011-10-27 | 2016-11-30 | Aminoalkilo-podstawiona pochodna n-tienylobenzamidu | |
| AU2014230552B2 (en) * | 2013-03-13 | 2017-11-16 | Chugai Seiyaku Kabushiki Kaisha | Dihydropyridazine-3,5-dione derivative |
-
2014
- 2014-03-13 AU AU2014230552A patent/AU2014230552B2/en active Active
- 2014-03-13 CA CA2901868A patent/CA2901868C/en active Active
- 2014-03-13 PL PL14765619T patent/PL2975030T3/pl unknown
- 2014-03-13 SG SG11201507345RA patent/SG11201507345RA/en unknown
- 2014-03-13 BR BR112015022092-4A patent/BR112015022092B1/pt active IP Right Grant
- 2014-03-13 ES ES14765619T patent/ES2811126T3/es active Active
- 2014-03-13 NZ NZ711182A patent/NZ711182A/en unknown
- 2014-03-13 WO PCT/JP2014/056778 patent/WO2014142273A1/ja not_active Ceased
- 2014-03-13 LT LTEP14765619.3T patent/LT2975030T/lt unknown
- 2014-03-13 EP EP20185235.7A patent/EP3757093A1/en active Pending
- 2014-03-13 MY MYPI2015703054A patent/MY174269A/en unknown
- 2014-03-13 UA UAA201509770A patent/UA118755C2/uk unknown
- 2014-03-13 TW TW106123450A patent/TWI683811B/zh active
- 2014-03-13 HU HUE14765619A patent/HUE050577T2/hu unknown
- 2014-03-13 TW TW103109058A patent/TWI596095B/zh active
- 2014-03-13 DK DK14765619.3T patent/DK2975030T3/da active
- 2014-03-13 HR HRP20201211TT patent/HRP20201211T1/hr unknown
- 2014-03-13 MX MX2015012537A patent/MX376532B/es active IP Right Grant
- 2014-03-13 RS RS20201171A patent/RS60911B1/sr unknown
- 2014-03-13 SI SI201431629T patent/SI2975030T1/sl unknown
- 2014-03-13 JP JP2015505576A patent/JP5814488B2/ja active Active
- 2014-03-13 CN CN201480013485.6A patent/CN105073715B/zh active Active
- 2014-03-13 RU RU2015143507A patent/RU2662832C2/ru active
- 2014-03-13 EP EP14765619.3A patent/EP2975030B1/en active Active
- 2014-03-13 KR KR1020167027514A patent/KR102072268B1/ko active Active
- 2014-03-13 KR KR1020157029079A patent/KR101664460B1/ko active Active
- 2014-03-13 PT PT147656193T patent/PT2975030T/pt unknown
- 2014-03-13 PE PE2015001917A patent/PE20151535A1/es unknown
-
2015
- 2015-08-25 IL IL240825A patent/IL240825B/en active IP Right Grant
- 2015-09-03 PH PH12015501940A patent/PH12015501940A1/en unknown
- 2015-09-09 CL CL2015002543A patent/CL2015002543A1/es unknown
- 2015-09-16 JP JP2015182722A patent/JP6420738B2/ja active Active
- 2015-09-22 CR CR20150505A patent/CR20150505A/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016040262A (ja) * | 2013-03-13 | 2016-03-24 | 中外製薬株式会社 | ジヒドロピリダジン−３，５−ジオン誘導体 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6420738B2 (ja) | ジヒドロピリダジン−３，５−ジオン誘導体 | |
| JP5916975B1 (ja) | ナトリウム依存性リン酸トランスポーター阻害剤を含有する医薬 | |
| WO2024044570A1 (en) | Compounds and methods for modulating her2 | |
| US9499553B2 (en) | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same | |
| RU2811864C1 (ru) | Фармацевтическое средство, содержащее ингибитор натрийзависимого переносчика фосфата | |
| HK1212700B (en) | Dihydropyridazine-3,5-dione derivative | |
| HK1235279A1 (en) | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150428 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150428 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20150428 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20150604 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150608 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150713 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150901 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150917 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5814488 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |